Don’t mistake activity for progress: Protecting early clinical programs from downstream delays

Early-stage milestones such as first participant enrollment, site activation and ethics sign-offs are naturally celebrated by biotech teams as signs that show momentum to investors. However, this visible movement doesn’t necessarily guarantee a program’s advancement if the timeline relies on unverified assumptions.

In this blog, I explore what sponsors can do to protect an asset’s value and why shifting the focus from short-term activity to predictable progress is necessary to ensure each milestone actively strengthens the program as studies progress.

Activity milestones vs. value milestones

When there is pressure to demonstrate fast progress to investors or board members, clinical teams may accept recruitment estimates or start-up timelines before stress-testing these against real-world conditions.

Building predictable progress requires a clear shift in the planning of clinical research projects, moving the conversation away from how quickly an activity can launch and instead focusing on the evidence needed in a trial to enable an asset to move forward. This key distinction outlines the difference between activity milestones and value milestones:

• Activity milestones show visible movement: Site activation, first participant enrolled and ethics approvals
• Value milestones deliver meaningful advancement: High-integrity, reproducible evidence generated and crucial regulatory queries answered. Establishing an objective basis needed for the next clinical or commercial decision.

Milestones that demonstrate activity show that work is underway, whereas those that provide value prove whether a program is moving closer to its ultimate regulatory and commercial goals.

How to build more predictable progress into your program

De-risking your program without stalling momentum requires three core actions:

1. Stress-test timeline assumptions before committing dates

Locking in target dates before stress-testing the assumptions behind them is one of the most common ways to create downstream friction in an early clinical program. Instead, clinical leaders should evaluate their operational readiness across several critical areas before committing dates to executives and investors:

• Site readiness: Evaluating current staffing and patient capacity rather than relying on previous records or an institution's reported prestige.
• Dependency readiness: Verifying lab setup, investigational product (IP) supply, vendor contracts and ethics review timelines before locking in dates.
• Decision ownership: Identifying who holds direct responsibility for every input that could derail execution to ensure accountability and quality control.

2. Close the gap in your evidence pathway

A protocol can pass feasibility checks and receive ethics clearance while still struggling to generate global-ready data. This breakdown happens when study objectives, endpoints and assessment schedules are developed in isolated silos rather than as a single, connected pathway.

Study objective → Endpoint selection → Assessment schedule → Captured data → Development decision

When challenges are encountered as study objectives evolve into development decisions, a trial can appear to be executed smoothly while missing critical data.

A study may aim to identify dose-response endpoints measured at timeframes that fail to demonstrate whether therapeutic effects are sustained. Additionally, omitting baseline variables can mean a trial defines patient cohorts without capturing critical baseline variables needed to interpret differences between populations later.

Cross-functional protocol reviews combining clinical execution, biometrics and regulatory expertise before site activation help eliminate these gaps early, ensuring each data point directly supports the next regulatory submission.

3. Turn emerging change into decisions

Clinical trials rarely go exactly to plan, so predictability often depends on how quickly emerging risks are surfaced while options remain open.

Active governance provides real-time visibility, allowing sponsors and contract research organizations (CROs) to act before delays disrupt later activities. This effective governance requires several clear elements, including understanding what changed and its downstream impact, pinpointing what specific input is waiting, assigning clear ownership for the response and establishing the exact deadline before subsequent milestones are compromised.

When holdups occur, teams must be able to pivot to structured recovery, resequencing unaffected tasks and tightening review cycles.

Predictable progress that holds up under scrutiny

When embarking on an early-phase clinical research program, the quality of evidence and regulatory foresight matter more than speed alone. Credibility is built when risks are identified as early as possible and timeline assumptions are tested to see if they hold up under pressure.

Building predictable progress requires realistic planning, transparent governance, and deep regulatory foresight. To find out more about how early planning decisions can protect your upcoming clinical milestones, read our latest whitepaper.

‍